Nucleic acid tests for clinical translation

M Li, F Yin, L Song, X Mao, F Li, C Fan, X Zuo… - Chemical …, 2021 - ACS Publications
Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), are
natural biopolymers composed of nucleotides that store, transmit, and express genetic …

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer

JM Lafky, JA Wilken, AT Baron, NJ Maihle - Biochimica et Biophysica Acta …, 2008 - Elsevier
The ERBB or EGF receptor (EGFR) proto-oncogene family, which consists of four structurally-
related transmembrane receptors (ie, EGFR, ErbB2, ErbB3, and ErbB4), plays an etiological …

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

JN McAlpine, KC Wiegand, R Vang, BM Ronnett… - BMC cancer, 2009 - Springer
Background The response rate of ovarian mucinous carcinomas to paclitaxel/carboplatin is
low, prompting interest in targeted molecular therapies. We investigated HER2 expression …

Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer

D Yang, Y He, B Wu, Y Deng, N Wang, M Li… - Journal of ovarian …, 2020 - Springer
Background Ovarian cancer (OC) ranks fifth as a cause of gynecological cancer-associated
death globally. Until now, the molecular mechanisms underlying the tumorigenesis and …

Advances in real‐time PCR: Application to clinical laboratory diagnostics

B Kaltenboeck, C Wang - Advances in clinical chemistry, 2006 - pmc.ncbi.nlm.nih.gov
The polymerase chain reaction (PCR) has become one of the most important tools in
molecular diagnostics, providing exquisite sensitivity and specificity for detection of nucleic …

HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients

M Tuefferd, J Couturier, F Penault-Llorca… - PloS one, 2007 - journals.plos.org
Background Despite a typically good response to first-line combination chemotherapy, the
prognosis for patients with advanced ovarian cancer remains poor because of acquired …

Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer

Y Cai, J Wang, L Zhang, D Wu, D Yu, X Tian, J Liu… - Medical oncology, 2015 - Springer
The present study was designed to explore the cross talk between fatty acid synthase
(FASN) and HER2 (ErbB2) in ovarian cancer. A total of 60 ovarian cancer patients and 15 …

Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer

A Serrano-Olvera, A Dueñas-González… - Cancer treatment …, 2006 - Elsevier
The HER2 oncogene encodes a transmembrane protein partially homologous to epidermal
growth factor receptor. This oncogene has been studied mainly in breast cancer where it has …

Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma

H Lassus, H Sihto, A Leminen, H Joensuu… - Journal of molecular …, 2006 - Springer
EGFR and erbB-2 are targets for specific cancer therapy. The purpose of this study was to
examine the frequency and clinicopathological correlations of gene amplification, protein …

Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer

V Goodell, LG Salazar, N Urban… - Journal of Clinical …, 2006 - ascopubs.org
Purpose Presence of intratumoral T-cell infiltration has been linked to improved survival in
ovarian cancer patients. We questioned whether antibody immunity specific for ovarian …